Search research articles
Contact Us
Filters
Showing results (181-190 of 282) with videos related to
Page
of 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer
Thomas John, Otavia L Caballero, Suzanne J Svobodová, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2010
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
Cora N Sternberg, Ian D Davis, Jozef Mardiak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2023
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N Sternberg, Ian D Davis, Jozef Mardiak, et al.
European Urology Oncology
|
October 8, 2023
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)
Andrew Weickhardt, Farshad Foroudi, Nathan Lawrentschuk, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 24, 2019
The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of <sup>18</sup>F-Fluoromethylcholine or <sup>68</sup>Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy
Ur Metser, Sue Chua, Bao Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2007
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma
Malcolm Ranson, Peter Hersey, Damien Thompson, et al.
Cancer Immunity
|
August 21, 2007
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma
Ian D Davis, Gregory A Wiseman, Fook-Thean Lee, et al.
British Journal of Cancer
|
November 20, 2025
Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy
Yiyue Zhu, Elaheh Zarean, Danmeng L Li, et al.
Cancer Immunity
|
July 17, 2003
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma
Jonathan Cebon, Elke Jäger, Mark J Shackleton, et al.
BJU International
|
October 17, 2013
Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the Prostate Cancer Registry
Sue M Evans, Jeremy L Millar, Mark Frydenberg, et al.
Page
of 29
Search research articles
Search
Showing results (181-190 of 282) with videos related to
Sort By:
Page
of 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer
Thomas John, Otavia L Caballero, Suzanne J Svobodová, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2010
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
Cora N Sternberg, Ian D Davis, Jozef Mardiak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2023
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N Sternberg, Ian D Davis, Jozef Mardiak, et al.
European Urology Oncology
|
October 8, 2023
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)
Andrew Weickhardt, Farshad Foroudi, Nathan Lawrentschuk, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 24, 2019
The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of <sup>18</sup>F-Fluoromethylcholine or <sup>68</sup>Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy
Ur Metser, Sue Chua, Bao Ho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2007
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma
Malcolm Ranson, Peter Hersey, Damien Thompson, et al.
Cancer Immunity
|
August 21, 2007
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma
Ian D Davis, Gregory A Wiseman, Fook-Thean Lee, et al.
British Journal of Cancer
|
November 20, 2025
Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy
Yiyue Zhu, Elaheh Zarean, Danmeng L Li, et al.
Cancer Immunity
|
July 17, 2003
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma
Jonathan Cebon, Elke Jäger, Mark J Shackleton, et al.
BJU International
|
October 17, 2013
Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the Prostate Cancer Registry
Sue M Evans, Jeremy L Millar, Mark Frydenberg, et al.
Page
of 29